![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: AR |
Gene summary for AR |
![]() |
Gene information | Species | Human | Gene symbol | AR | Gene ID | 367 |
Gene name | androgen receptor | |
Gene Alias | AIS | |
Cytomap | Xq12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P10275 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
367 | AR | GSM4909282 | Human | Breast | IDC | 8.07e-06 | -1.87e-01 | -0.0288 |
367 | AR | GSM4909285 | Human | Breast | IDC | 8.07e-06 | -1.82e-01 | 0.21 |
367 | AR | GSM4909286 | Human | Breast | IDC | 1.72e-05 | -1.87e-01 | 0.1081 |
367 | AR | GSM4909287 | Human | Breast | IDC | 2.91e-04 | -1.82e-01 | 0.2057 |
367 | AR | GSM4909290 | Human | Breast | IDC | 3.95e-05 | 3.05e-01 | 0.2096 |
367 | AR | GSM4909291 | Human | Breast | IDC | 8.28e-03 | -1.87e-01 | 0.1753 |
367 | AR | GSM4909293 | Human | Breast | IDC | 2.02e-73 | 1.07e+00 | 0.1581 |
367 | AR | GSM4909298 | Human | Breast | IDC | 4.69e-05 | 1.52e-01 | 0.1551 |
367 | AR | GSM4909301 | Human | Breast | IDC | 2.32e-27 | 7.04e-01 | 0.1577 |
367 | AR | GSM4909303 | Human | Breast | IDC | 1.07e-07 | 5.92e-01 | 0.0438 |
367 | AR | GSM4909306 | Human | Breast | IDC | 1.70e-27 | 6.27e-01 | 0.1564 |
367 | AR | GSM4909307 | Human | Breast | IDC | 5.11e-04 | 2.83e-01 | 0.1569 |
367 | AR | GSM4909308 | Human | Breast | IDC | 3.47e-09 | 3.55e-01 | 0.158 |
367 | AR | GSM4909309 | Human | Breast | IDC | 1.10e-02 | -1.66e-01 | 0.0483 |
367 | AR | GSM4909311 | Human | Breast | IDC | 9.12e-06 | -8.10e-02 | 0.1534 |
367 | AR | GSM4909313 | Human | Breast | IDC | 2.86e-05 | 3.06e-01 | 0.0391 |
367 | AR | GSM4909319 | Human | Breast | IDC | 5.65e-03 | -1.17e-01 | 0.1563 |
367 | AR | M5 | Human | Breast | IDC | 2.93e-07 | 7.39e-01 | 0.1598 |
367 | AR | P1 | Human | Breast | IDC | 2.51e-02 | 9.14e-02 | 0.1527 |
367 | AR | NAFLD1 | Human | Liver | NAFLD | 8.87e-12 | 1.11e+00 | -0.04 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
GO:00061199 | Breast | Precancer | oxidative phosphorylation | 53/1080 | 141/18723 | 1.15e-29 | 2.04e-26 | 53 |
GO:00090608 | Breast | Precancer | aerobic respiration | 58/1080 | 189/18723 | 5.69e-27 | 7.62e-24 | 58 |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00453338 | Breast | Precancer | cellular respiration | 59/1080 | 230/18723 | 5.97e-23 | 5.32e-20 | 59 |
GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
GO:00196468 | Breast | Precancer | aerobic electron transport chain | 34/1080 | 87/18723 | 3.95e-20 | 2.64e-17 | 34 |
GO:00427738 | Breast | Precancer | ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
GO:00427758 | Breast | Precancer | mitochondrial ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:00229048 | Breast | Precancer | respiratory electron transport chain | 35/1080 | 114/18723 | 8.51e-17 | 3.26e-14 | 35 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:00229008 | Breast | Precancer | electron transport chain | 42/1080 | 175/18723 | 1.37e-15 | 4.59e-13 | 42 |
GO:19026008 | Breast | Precancer | proton transmembrane transport | 39/1080 | 157/18723 | 4.18e-15 | 1.18e-12 | 39 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
GO:00067547 | Breast | Precancer | ATP biosynthetic process | 21/1080 | 57/18723 | 2.31e-12 | 4.26e-10 | 21 |
GO:20001169 | Breast | Precancer | regulation of cysteine-type endopeptidase activity | 43/1080 | 235/18723 | 1.30e-11 | 1.83e-09 | 43 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052159 | Prostate | BPH | Prostate cancer | 48/1718 | 97/8465 | 1.08e-10 | 1.87e-09 | 1.16e-09 | 48 |
hsa0521514 | Prostate | BPH | Prostate cancer | 48/1718 | 97/8465 | 1.08e-10 | 1.87e-09 | 1.16e-09 | 48 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
GZMA | PARD3 | GZMA_PARD3 | PARs | Breast | ADJ |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | DCIS |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | Healthy |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | IDC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Cervix | ADJ |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | Cervix | CC |
CTSG | PARD3 | CTSG_PARD3 | PARs | Cervix | CC |
GZMA | PARD3 | GZMA_PARD3 | PARs | Cervix | CC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Cervix | CC |
C5 | C5AR1 | HC_C5AR1 | COMPLEMENT | Cervix | CC |
EDA | EDAR | EDA_EDAR | EDA | Cervix | CC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Cervix | Precancer |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | CRC | AD |
CTSG | PARD3 | CTSG_PARD3 | PARs | CRC | AD |
GZMA | PARD3 | GZMA_PARD3 | PARs | CRC | AD |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | CRC | ADJ |
CTSG | PARD3 | CTSG_PARD3 | PARs | CRC | ADJ |
GZMA | PARD3 | GZMA_PARD3 | PARs | CRC | ADJ |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | CRC | CRC |
PRSS3 | PARD3 | PRSS3_PARD3 | PARs | CRC | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | rs137852569 | c.1789N>A | p.Ala597Thr | p.A597T | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FC-A8O0-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 6 | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | rs137852573 | c.1823N>A | p.Arg608Gln | p.R608Q | P10275 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-VP-A875-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | c.710N>G | p.Lys237Arg | p.K237R | P10275 | protein_coding | tolerated_low_confidence(0.21) | probably_damaging(0.997) | TCGA-BR-6454-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
AR | SNV | Missense_Mutation | c.2440N>C | p.Phe814Leu | p.F814L | P10275 | protein_coding | tolerated(0.54) | probably_damaging(0.927) | TCGA-BR-7704-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
AR | SNV | Missense_Mutation | c.1165N>A | p.Leu389Met | p.L389M | P10275 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-BR-8361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
AR | SNV | Missense_Mutation | c.895G>A | p.Ala299Thr | p.A299T | P10275 | protein_coding | tolerated_low_confidence(0.08) | benign(0.102) | TCGA-BR-8372-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | etoposide | CR | |
AR | SNV | Missense_Mutation | rs754201976 | c.1847N>A | p.Arg616His | p.R616H | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BR-A4PE-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | rs137852572 | c.2324N>A | p.Arg775His | p.R775H | P10275 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-CD-8531-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | epirubicin | CR |
AR | SNV | Missense_Mutation | c.1805N>A | p.Cys602Tyr | p.C602Y | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CD-A4MI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
AR | SNV | Missense_Mutation | c.2440N>G | p.Phe814Val | p.F814V | P10275 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-CD-A4MJ-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | QUININE SULFATE | QUININE SULFATE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | NILUTAMIDE | NILUTAMIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | ARN-509 | APALUTAMIDE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | CRUFOMATE | CRUFOMATE | ||
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | 2-AMINOFLURENE | CHEMBL84472 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 |